Recent Quotes (30 days)

You have no recent quotes
chg | %

Sernova Corp.  

(Public, CVE:SVA)   Watch this stock  
Find more results for SVA
+0.020 (6.90%)
Delayed:   3:49PM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.30 - 0.32
52 week 0.17 - 0.40
Open 0.30
Vol / Avg. 312,350.00/143,330.00
Mkt cap 45.12M
P/E     -
Div/yield     -
EPS -0.02
Shares 143.03M
Beta 0.78
Inst. own     -
Mar 15, 2016
Q1 2016 Sernova Corp Earnings Release

Key stats and ratios

Q1 (Jan '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -78.59% -79.71%
Return on average equity -98.28% -84.92%
CDP Score - -


700 Collip Cir Suite 114
+1-519-8585184 (Phone)
+1-519-8585099 (Fax)

Website links


Sernova Corp. is a Canada-based development-stage regenerative medicine company. The Company is focused on commercializing the Cell Pouch, a scalable, implantable, medical device for the transplantation and survival of therapeutic cells, which then release proteins and hormones for the long-term treatment of various diseases, such as diabetes, hemophilia and thyroid disease. The Company is also developing Sertolin and other local immune protection technologies to create an immune privileged environment and protect the Cell Pouch transplant. The Company's primary program is the clinical development of the Cell Pouch for treatment of patients with insulin-dependent diabetes. The Cell Pouch enables islets to be transplanted subcutaneously.

Officers and directors

Frank A. Holler Chairman of the Board
Age: 57
Philip Toleikis President, Chief Executive Officer
Ralph Deiterding CPA Chief Financial Officer
James T. Parsons CPA Director
Bruce Weber Director
Jeffrey A. Bacha Independent Director
Age: 47